Regencell Bioscience Valuation
RGC Stock | USD 5.91 0.04 0.68% |
At this time, the company appears to be overvalued. Regencell Bioscience holds a recent Real Value of $5.07 per share. The prevailing price of the company is $5.91. Our model determines the value of Regencell Bioscience from analyzing the company fundamentals such as Return On Equity of -0.43, shares outstanding of 13.01 M, and Shares Owned By Institutions of 0.19 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Regencell Bioscience's valuation include:
Price Book 9.2941 | Enterprise Value 68.5 M | Enterprise Value Ebitda (44.58) |
Overvalued
Today
Please note that Regencell Bioscience's price fluctuation is very risky at this time. Calculation of the real value of Regencell Bioscience is based on 3 months time horizon. Increasing Regencell Bioscience's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Regencell Bioscience is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Regencell Stock. However, Regencell Bioscience's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. Historical | Market 5.91 | Real 5.07 | Hype 5.8 | Naive 4.74 |
The real value of Regencell Stock, also known as its intrinsic value, is the underlying worth of Regencell Bioscience Company, which is reflected in its stock price. It is based on Regencell Bioscience's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Regencell Bioscience's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Regencell Bioscience Holdings helps investors to forecast how Regencell stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Regencell Bioscience more accurately as focusing exclusively on Regencell Bioscience's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Regencell Bioscience's intrinsic value based on its ongoing forecasts of Regencell Bioscience's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Regencell Bioscience's closest peers. If more than one evaluation category is relevant for Regencell Bioscience we suggest using both methods to arrive at a better estimate.
Regencell Bioscience Cash |
|
Regencell Valuation Trend
Comparing Regencell Bioscience's enterprise value against its market capitalization is a good way to estimate the value of Regencell Bioscience Holdings uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Regencell Bioscience Total Value Analysis
Regencell Bioscience Holdings is at this time forecasted to have company total value of 68.51 M with market capitalization of 76.39 M, debt of 85.74 K, and cash on hands of 59.41 K. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the Regencell Bioscience fundamentals before making security assessment based on enterprise value of the companyTakeover Price | Market Cap | Debt Obligations | Cash |
68.51 M | 76.39 M | 85.74 K | 59.41 K |
Regencell Bioscience Asset Utilization
One of the ways to look at asset utilization of Regencell is to check how much profit was generated for every dollar of assets it reports. Regencell Bioscience holds a negative application of assets of -0.28 pct., losing $0.002811 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of Regencell Bioscience Holdings shows how discouraging it operates for each dollar spent on its assets.Regencell Bioscience Ownership Allocation
The market capitalization of Regencell Bioscience is $76.39 Million. Regencell Bioscience holds majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 88.81 pct. of Regencell Bioscience outstanding shares that are owned by insiders implies they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that on December 21, 2017, Senator Michael Bennet of US Senate acquired $500,001 - $1,000,000 worth of Regencell Bioscience's common stock.Regencell Bioscience Profitability Analysis
Reported Net Loss for the year was (4.36 M) with profit before taxes, overhead, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Regencell Bioscience's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Regencell Bioscience and how it compares across the competition.
About Regencell Bioscience Valuation
The stock valuation mechanism determines Regencell Bioscience's current worth on a weekly basis. Our valuation model uses a comparative analysis of Regencell Bioscience. We calculate exposure to Regencell Bioscience's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Regencell Bioscience's related companies.Last Reported | Projected for Next Year | ||
Gross Profit | -745.6 K | -708.3 K | |
Pretax Profit Margin | 0.08 | 0.09 | |
Operating Profit Margin | 0.10 | 0.12 | |
Net Profit Margin | 0.04 | 0.05 | |
Gross Profit Margin | 1.11 | 0.98 |
Regencell Bioscience Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
Common Stock Shares Outstanding | 13 M |
Regencell Bioscience Current Valuation Indicators
Valuation refers to the process of determining the present value of Regencell Bioscience Holdings and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Regencell we look at many different elements of the entity such as Regencell's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Regencell Bioscience, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Regencell Bioscience's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Regencell Bioscience's worth.Complementary Tools for Regencell Stock analysis
When running Regencell Bioscience's price analysis, check to measure Regencell Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regencell Bioscience is operating at the current time. Most of Regencell Bioscience's value examination focuses on studying past and present price action to predict the probability of Regencell Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regencell Bioscience's price. Additionally, you may evaluate how the addition of Regencell Bioscience to your portfolios can decrease your overall portfolio volatility.
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |